Why Did CRISPR Therapeutics (CRSP) Stock Slide After Its Latest Update?
Yahoo Finance · Nov 3, 2026 · Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics (CRSP) has released its third quarter 2026 results, reporting revenue of US$12.67 million and a net loss of US$111.44 million, providing investors with updated financial data to review. The latest quarterly update and pipeline news landed against a backdrop where CRISPR Therapeutics’ share price has eased 9.81% over the past 30 days and 7.03% year to date, while its 1 year total shareholder return has declined 19.33%. This signals fading momentum despite recent clinical...
Not investment advice. Headline and summary only, not a full reprint.